Abstract
Hyperoxia leads to oxidative modification and damage of macromolecules in the respiratory tract with loss of biological functions. Given the lack of antioxidant gene induction with acute exposure to 100% oxygen, we hypothesized that clearance pathways for oxidatively modified proteins may be induced and serve in the immediate cellular response to preserve the epithelial layer. To test this, airway epithelial cells were obtained from individuals under ambient oxygen conditions and after breathing 100% oxygen for 12 h. Gene expression profiling identified induction of genes in the chaperone and proteasome-ubiquitin-conjugation pathways that together comprise an integrated cellular response to manage and degrade damaged proteins. Analyses also revealed gene expression changes associated with oxidoreductase function, cell cycle regulation, and ATP synthesis. Increased HSP70, protein ubiquitination, and intracellular ATP were validated in cells exposed to hyperoxia in vitro. Inhibition of proteasomal degradation revealed the importance of accelerated protein catabolism for energy production of cells exposed to hyperoxia. Thus, the human airway early response to hyperoxia relies predominantly upon induction of cytoprotective chaperones and the ubiquitin-proteasome–dependent protein degradation system to maintain airway homeostatic integrity.
Keywords: airways, gene expression, hyperoxia, proteasome, ubiquitin
Oxygen, one of the most abundant elements in our world, is essential for the oxidation of organic compounds to generate the energy needed to sustain life. Under ambient conditions, reactive oxygen species (ROS) are generated at a low level in lung cells during aerobic metabolism. To minimize the oxidant injury that is a consequence of aerobic life, the human lung is endowed with an integrated antioxidant system, which detoxifies reactive products (1–4). However, excessive ROS may overwhelm the antioxidant system and result in damage to major cellular components, including membrane lipids, proteins, carbohydrates, and DNA (1, 5–8). The pathophysiologic consequences of this injury may include cell death, and tissue inflammation and damage. This is particularly evident during conditions of increased oxygen exposure for medical therapy (4, 9, 10). The bronchial epithelium is particularly vulnerable to the effects of airborne oxidative stress as the moist mucosal surface of the airway is in direct contact with the environment (11). Hyperoxia leads to oxidant injury in the respiratory tract, which is manifest as acute tracheobronchitis with edema and decrease in mucociliary clearance (12, 13). Oxidative damage of proteins and loss of biological function is one defined end-point of hyperoxic injury (1, 5–8). In the past, significant attention has focused on clarifying the role of antioxidant enzymes such as superoxide dismutases, catalase, or glutathione peroxidases in mitigating airway damage resulting from hyperoxia (6, 7, 12, 14, 15). Studies show that exposure to lower levels of hyperoxia can lead to upregulation of antioxidant defenses, which are protective in subsequent high-level (> 95%) oxygen exposure (1). However, most studies also show that in response to immediate exposure to > 95% oxygen, antioxidant enzymes are expressed at low levels, and are unable to upregulate rapidly enough to protect against injury (6, 7, 12, 15). In this context, we hypothesized that in the absence of increased protection against oxidative injury, clearance pathways for oxidatively damaged proteins may have a central role in the early response of cells to maintain the homeostatic integrity of the epithelial layer. Substantial evidence indicates that the ubiquitin-proteasome system is responsible for degrading altered proteins in the cytoplasm, nucleus, and endoplasmic reticulum of eukaryotic cells (16). Using a functional genomic approach, we analyzed the mRNA levels of human bronchial epithelial cells obtained by brushing at bronchoscopy from healthy volunteers before and after 12 h exposure to > 95% oxygen. Genes related to proteasome ubiquitin-dependent protein catabolism, cell cycle, or with an oxidoreductase activity were identified as primary early responses to in vivo hyperoxia. In complementary studies, the induction of chaperones, ATP synthesis, and increased ubiquitination was confirmed in human airway epithelial cells exposed to hyperoxia in vitro.
MATERIALS AND METHODS
Study Population and Exposure to Hyperoxia In Vivo
To evaluate human bronchial epithelial cell hyperoxia-related gene expression in vivo, healthy nonsmoking volunteers were studied. All had normal histories, physical examinations, chest X-ray, and spirometry. Exclusion criteria included prolonged exposure to second-hand smoke at home or work; exposure to environmental dusts or toxic agents known to cause pulmonary disease; a history of recurrent episodes of breathlessness, chest tightness, cough, and/or sputum production; human immunodeficiency virus infection; and a history of respiratory infection in the previous 6 wk (7, 12). Volunteers underwent fiberoptic bronchoscopy with cytology brushings from the right main stem bronchus to obtain bronchial epithelial cells at room air (group normoxia). They returned 2 wk later and were exposed at > 95% oxygen for 12 h by a full, tight-fitting mask, after which they immediately underwent a bronchoscopy for sampling of bronchial epithelial cells (group hyperoxia) as previously described (7, 12, 17). In addition, other healthy volunteers underwent bronchoscopy to collect bronchial epithelial cells for culture with exposure to normoxia and hyperoxia in vitro. The study was approved by the Institutional Review Board, and written informed consent was obtained from all volunteers.
Preparation of RNA and Microarray Hybridization
Normal bronchial epithelial cells were obtained by cytology brushings from second- and third-order bronchi as previously described (12). Total RNA from fresh human bronchial epithelial cells was isolated by the Guanidium Thiocyanate-Cesium Chloride (GTC-CsCl) gradient method, and first subjected to formaldehyde-agarose gel electrophoresis to confirm its integrity. Samples showing degradation of ribosomal RNA by visual inspection under ultraviolet light were discarded. Total RNA (8 μg) was converted into double-stranded cDNA with the SuperScript II reverse transcriptase (Invitrogen, Carlsbad, CA) using an oligo(18)24 primer containing a T7 RNA polymerase promoter (Genset, La Jolla, CA). cDNAs were purified by phenol/chloroform extraction and ethanol precipitation. The cDNA was used as a template for synthesis of the biotinylated cRNA transcript using the BioArray RNA transcript labeling kit (Enzo Diagnostics, Farmingdale, NY). cRNAs were purified from an in vitro transcription reaction using RNeasy kit (Qiagen, Valencia, CA). After fragmentation into ∼ 200 bp by alkaline treatment (200 mM tris-acetate, pH 8.2/500 mM potassium acetate/ 150 mM magnesium acetate), biotinylated cRNA was hybridized to the test chip as specified by Affymetrix; when satisfactory, 15μg of the labeled cRNA were hybridized overnight onto the Affymetrix HG-U133A GeneChip (Affymetrix, Santa Clara, CA), which contained 22,283 human transcripts. After hybridization, each array was washed and stained according to the Affymetrix protocol EukGE-WS2v4, and scanned (GeneArray scanner G2500A; Hewlett-Packard, Palo Alto, CA). The methodology used in our study fulfilled the Microarray Gene Expression Data Society (MGED) Minimum Information About a Microarray Experiment (MIAME) guidelines (www.mged.org/Workgroups/MIAME/miame.html).
Microarray Data Acquisition and Preprocessing
From data image files, gene transcript levels were determined using algorithms from the Microarray Analysis Suite version 5.1 software (Affymetrix). Based on the detected P value, a single weighted mean expression level for each gene was obtained, as well as the absolute call (designated “Present,” “Marginal,” or “Absent”), indicating if the transcript was reliably detected using a one-sided Wilcoxon signed-rank test. Data was scaled from each array to normalize the results for interarray comparisons by correcting the mean intensity for each array (top and bottom 2% of genes excluded) to a set target intensity of 300. Arrays were assessed for several quality control measures, including the absence of any significant artifacts, the detection P value < 0.05 (called “Present”) for the bacterial genes spiked into the hybridization mix, the 3′/5′ ratio of the intensity for β-actin and GADPH, the percent of genes detected as “Present” in each array. Finally, probe sets designated as “Absent” were filtered out in all arrays.
Microarray Data Analysis
The raw data, normalized using the GeneSpring software (Silicon Genetics, Redwood City, CA), was performed as follows: (1) per microarray sample, by dividing the raw data by the 50th percentile of all measurements; and (2) per gene, by dividing the raw data by the median of the expression level for the gene in all samples. All further analyses were performed on the 9,787 normalized genes from 8 chips. The gene annotations for each probe set were updated with the latest NetAffx HG-U133A annotation file (09–16–2005) at: http://www.affymetrix.com/support/technical/byproduct.affx?product=hgu133-20 (19). Assessment of genes with significant change was performed using the GeneSpring software, by calculating the P values using the Welch t test. This analysis was done on the 9,787 genes from 8 chips. Genes were assumed to be significantly upregulated or downregulated if the calculated P value was < 0.05. The mean value of expression for a given gene in hyperoxia and normoxia was used to determine the fold change in a gene expression between the two conditions. Hierarchical clustering of the genes among samples from individuals in normoxia and in hyperoxia was performed by a Pearson correlation (uncentered) similarity metric and average linkage clustering using the GeneSpring software tools applying Eisen's methodology (20). Selected genes were subjected to an intensive search to identify biological function and associated regulatory pathways. Genes were classified based on the Gene Ontology Consortium (21) obtained through the NetAffx server (available at www.netaffx.com), public information from GenBank (www.ncbi.nlm.nih.gov/Genbank/index.html), and SOURCE search (http://genome-www5.stanford.edu/cgi-bin/source/sourceSearch) for biological process. To identify functional categories that were modulated by hyperoxia, we used the GOMINER software developed by Zeeberg and coworkers, which gives a P value for Gene Ontology (GO) categories that are enriched in significantly modulated genes (22).
Cell Culture and In Vitro Hyperoxia
BET-1A cells, a human bronchial epithelial cell line transformed by SV-40 T antigen (23), was cultured in a serum-free LHC-9 medium consisting of LHC-8 medium (Biofluids, Rockville, MD), 2.75 M epinephrine, 0.33 nM retinoic acid, 25 U/ml penicillin, 25 μg/ml streptomycin, and 25 μg/ml fungizone (Invitrogen), on plates precoated with coating medium containing 29 μg/ml collagen (Vitrogen, Palo Alto, CA), 10 μg/ml bovine serum albumin (Biofluids, Camarillo, CA), and 10 μg/ml fibronectin (Calbiochem, La Jolla, CA). Primary human airway epithelial cells (HAEC) obtained by bronchial brushing from healthy volunteers were cultured in serum-free Lechner and LaVeck media (LHC8) on plates precoated with coating media as above (24). Primary HAEC cultures of passages 0–2 were used in experiments. HAEC or BET-1A were placed in a humidified incubator chamber (MIC-101; Billups-Rothenburg, Del Mar, CA), and the chamber inlet port connected to a source of pure oxygen infused at 5 liters/min. Oxygen concentration was monitored at the outlet port, and when oxygen was > 98% in the chamber, the gas source was disconnected and inlet and outlet ports tightly clamped. The chamber was maintained in an incubator at 37°C for the duration of the exposure, and the oxygen monitored at the end of the exposure. At end of exposures of up to 24 h oxygen levels were 98 ± 2%. After exposure, the cells were rinsed three times with phosphate-buffered saline and harvested for RNA and protein extracts.
To evaluate the effect of hyperoxia on ubiquitination of proteins, 50 μM proteasome inhibitor Ac-Leu-Leu-nLeu-al (ALLN; Santa Cruz Biotechnology, Santa Cruz, CA) was added before hyperoxia to block proteasome degradation.
Northern Blot Analysis
Total RNA from cells was extracted by the GTC ([4 M guanidium thiocyanate, 25 mM sodium citrate, pH 7.0], 0.5% sarkosyl, and 0.1 M β–mercaptoethanol)-CsCl gradient method and evaluated by Northern blot using a [32P]-labeled Heat Shock Protein 70 (HSP70) probe (25, 26) and [32P]-labeled 18S ribosomal RNA as a control. The blots were then subjected to autoradiography and the HSP70 bands quantified relative to 18S ribosomal RNA using a PhosphorImager (Molecular Dynamics, Sunnyvale, CA).
Western Blot Analysis
BET-1A cells were harvested in an ice-cold buffer containing 50 mM Tris (pH 7.9), 50 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol (DTT), 0.5% Nonidet P-40, 10% glycerol, 1 mM phenylmethylsulphonylfluoride (PMSF), 5 μg/ml leupeptin, 10 μg/ml pepstatin A, 200 μM sodium orthovanadate (NaOV), and 20 μg/ml aprotinin (24, 27). Cell lysates (70 μg/lane) were separated by electrophoresis on 15% SDS-PAGE HCl gel and then electrophoretically transfered onto a nitocellulose membrane or onto Immuno-Blot PVDF Membrane (0.2 μm; Bio-Rad, Hercules, CA). The membrane was blocked with 5% nonfat milk or 5% bovine serum albumin (BSA; Biosource, Rockville, MD), and incubated overnight with primary antibodies. Antibodies included monoclonal anti-ubiquitin antibody P4D1 (Santa Cruz Biotechnology), the rabbit polyclonal cleaved caspase-8 antibody (Cell Signaling Technology, Danvers, MA), the mouse monoclonal anti–β-actin antibody AC-15 (Sigma-Aldrich, St. Louis, MO), and the secondary antibody was conjugated to horseradish peroxidase. The detection of signal was performed with enhanced chemiluminescent system (ECL; Amersham, Arlington Heights, IL).
Measurement of Intracellular ATP Concentration
Whole cell protein extracts from BET-1A cells were harvested as described above. ATP concentration within lysates was detected using the ATPlite Luminescence ATP Detection Assay System (PerkinElmer, Boston, MA). Values were normalized for protein concentrations of the lysate.
RESULTS
Clinical Assessment of Healthy Volunteers and Biological Samples
Global characteristics of healthy volunteers included average age of 27 ± 2 yr, 3 females, and all were white. The major epithelial cell types obtained by brushing at bronchoscopy included ciliated, secretory, basal, and undifferentiated cells, and a small number of inflammatory cells as previously reported (7). A total of six individuals were analyzed by microarray. Two chips, representing paired RNA from one volunteer under normoxia and hyperoxia, displayed a poor microarray quality score and were not used in analyses. Of the remaining five individuals, RNA was degraded in one of the five under normoxia, and in another one of five under hyperoxia. Thus eight chips representing five individuals, with three of the five individuals having paired data before and after hyperoxia, were of good quality and used in analyses (Table 1).
TABLE 1.
Name | Background < 100 | Noise < 5 | Scale Factor* | %P† | 3′/5′ β-actin < 2 | 3′/5′ GAPDH < 2 |
---|---|---|---|---|---|---|
1-normoxia | 59 | 2.5 | 13.4 | 42 | 2.5 | 1.6 |
2-normoxia | 89 | 3.8 | 4.4 | 52 | 1.2 | 0.9 |
2-hyperoxia | 80 | 3.3 | 4.2 | 54 | 1.3 | 1.1 |
3-normoxia | 100 | 4.2 | 6.1 | 46 | 1.4 | 1,0 |
3-hyperoxia | 93 | 3.9 | 3.6 | 54 | 1.2 | 1,0 |
4-normoxia | 70 | 3.1 | 6.1 | 53 | 1.0 | 0.9 |
4-hyperoxia | 84 | 3.5 | 10.6 | 46 | 1.2 | 0.8 |
5-hyperoxia | 81 | 3.6 | 8.2 | 50 | 1.4 | 0.9 |
Mean (70) | 82 (13) | 3.5 (0.5) | 7.1 (3.4) | 50 (4) | 1.4 (0.5) | 1 (0.2) |
Definition of abbreviation: GAPDH, glyceraldehyde phosphate deydrogenase.
Scaling factor of the mean intensity for each array to a set target intensity of 300.
Percent of genes detected as Present by the Microarray Suite 5.1 software.
Global Analysis of Gene Expression Profiles
Based on the selection of genes called “Present,” and those found in at least three of four chips in each condition (normoxia or hyperoxia), a total of 9,787 genes were identified in the final set of analyzed genes. Based on the Welch t test, we identified 135 genes (1.4% of the total genes) significantly modulated by hyperoxia—that is, 97 up-regulated genes and 38 down-regulated genes (Tables 2 and 3). Fold change of modulated genes was modest: 6% of these genes displayed on average ± 60% variation in hyperoxia versus normoxia, 19% displayed ± 40–60% variation, 58% displayed ± 20–40% variation, and 17% of the genes had < 20% variation. Consequently, the P value for each gene from the Welch t test was obtained without any correction for false discovery rate (Figure 1). The effects of hyperoxia were also assessed through the complementary approach of global analysis of gene expression by the clustering method. This approach identified individuals rather than the hyperoxia exposure within the whole set of 9,787 genes (Figure 2A). Hyperoxia exposure was discriminated by gene expression profile when the subgroup of genes for analyses was selected upon the P value < 0.05 (i.e., the set of 135 significantly modulated genes; Figure 2B). To mitigate any difficulty with false detection, we focused on the functional categories according to the Gene Ontology (GO) denomination rather than on the modulation of specific genes by themselves. Functional analysis was extrapolated through the GO categories for each gene, with the aid of the GOMINER software (22) (Table 4). This approach identified the involvement of several groups of genes with particular known molecular functions and biological processes and thus helps the understanding of the complex integrated hyperoxia-induced cell response (Figures 3A and 3B). Categories of genes involved in protein modification were predominantly identified, especially genes with oxidoreductase activity and those involved in ubiquitination. There was also induction of genes involved in ATP synthesis. Of note, a group of genes with unknown function was also identified. Some of these, however, belong to well-defined categories such as the ubiquitin-dependent protein catabolism for PSMD9 or protein ser/thr/tyr kinase activity for LIMK2; the grouping shown is inherent to the GO classification.
TABLE 2.
Affymetrix ID | Accession No. | Symbol | Gene | Ratio* | P Value† |
---|---|---|---|---|---|
221904_at | NM_144635 | MGC21688 | Hypothetical protein MGC21688 | 0.73 | 2.5 × 10−3 |
219001_s_at | NM_024345 | MGC10765 | Hypothetical protein MGC10765 | 0.66 | 3.4 × 10−3 |
221774_x_at | NM_017569 | FAM48A | Family with sequence similarity 48, member A | 0.64 | 3.7 × 10−3 |
32091_at | NM_014655 | KIAA0446 | KIAA0446 gene product | 0.81 | 7.2 × 10−3 |
204676_at | NM_015421 | DKFZP564K2062 | DKFZP564K2062 protein | 0.67 | 1.2 × 10−2 |
204252_at | NM_001798 | CDK2 | Cyclin-dependent kinase 2 | 0.72 | 1.3 × 10−2 |
212083_at | NM_144582 | TEX261 | Testis expressed gene 261 | 0.85 | 1.3 × 10−2 |
200856_x_at | NM_006311 | NCOR1 | Nuclear receptor co-repressor 1 | 0.61 | 1.6 × 10−2 |
204180_s_at | NM_014007 | ZNF297B | Zinc finger protein 297B | 0.80 | 1.7 × 10−2 |
206115_at | NM_004430 | EGR3 | Early growth response 3 | 0.40 | 1.8 × 10−2 |
213816_s_at | NM_000245 | MET | Met proto-oncogene (hepatocyte growth factor receptor) | 0.67 | 1.9 × 10−2 |
201860_s_at | NM_000930 | PLAT | Plasminogen activator, tissue | 0.64 | 1.9 × 10−2 |
219801_at | NM_030580 | ZNF34 | Zinc finger protein 34 (KOX 32) | 0.69 | 2.1 × 10−2 |
215246_at | NM_016648 | HDCMA18P | HDCMA18P protein | 0.77 | 2.3 × 10−2 |
203934_at | NM_002253 | KDR | Kinase insert domain receptor (a type III receptor tyrosine kinase) | 0.75 | 2.5 × 10−2 |
201668_x_at | NM_002356 | MARCKS | Myristoylated alanine-rich protein kinase C substrate | 0.83 | 2.7 × 10−2 |
37433_at | NM_004671 | PIAS2 | Protein inhibitor of activated STAT2 | 0.64 | 2.7 × 10−2 |
201270_x_at | NM_015332 | KIAA1068 | KIAA1068 protein | 0.84 | 2.8 × 10−2 |
206533_at | NM_000745 | CHRNA5 | Cholinergic receptor, nicotinic, α polypeptide 5 | 0.72 | 2.9 × 10−2 |
214801_at | NM_145034 | LOC163590 | AF464140 | 0.66 | 3.0 × 10−2 |
216396_s_at | NM_004879 | EI24 | Etoposide induced 2.4 mRNA | 0.78 | 3.0 × 10−2 |
209594_x_at | NM_002784 | PSG9 | Pregnancy-specific β1-glycoprotein 9 | 0.78 | 3.0 × 10−2 |
217156_at | NM_000182 | HADHA | Hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A thiolase/enoyl-Coenzyme A hydratase (trifunctional protein), α subunit | 0.66 | 3.1 × 10−2 |
219685_at | NM_021637 | FLJ14084 | Hypothetical protein FLJ14084 | 0.73 | 3.2 × 10−2 |
210653_s_at | NM_000056 | BCKDHB | Branched chain keto acid dehydrogenase E1, β polypeptide (maple syrup urine disease) | 0.79 | 3.2 × 10−2 |
217866_at | NM_024811 | FLJ12529 | Pre-mRNA cleavage factor I, 59-kD subunit | 0.86 | 3.5 × 10−2 |
213058_at | AK092338 | LOC283585 | Transcribed locus, weakly similar to XP_375099.1 hypothetical protein LOC283585 | 0.63 | 3.6 × 10−2 |
214699_x_at | NM_015610 | DKFZP434J154 | WIPI49-like protein 2 | 0.72 | 3.6 × 10−2 |
217682_at | NM_014117 | PRO0149 | PRO0149 protein | 0.80 | 3.6 × 10−2 |
205741_s_at | NM_001392 | DTNA | Dystrobrevin, α | 0.72 | 3.9 × 10−2 |
218862_at | NM_024701 | ASB13 | Ankyrin repeat and SOCS box-containing 13 | 0.82 | 4.1 × 10−2 |
214119_s_at | NM_000801 | FKBP1A | FK506 binding protein 1A, 12 kD | 0.68 | 4.1 × 10−2 |
219889_at | NM_005479 | FRAT1 | Frequently rearranged in advanced T-cell lymphomas | 0.81 | 4.2 × 10−2 |
207805_s_at | NM_002813 | PSMD9 | Proteasome (prosome, macropain) 26S subunit, non-ATPase, 9 | 0.79 | 4.4 × 10−2 |
214080_x_at | NM_002743 | PRKCSH | Protein kinase C substrate 80K-H | 0.82 | 4.4 × 10−2 |
214035_x_at | AK131084 | LOC399491 | LOC399491 protein | 0.65 | 4.6 × 10−2 |
205550_s_at | NM_004899 | BRE | Bain and reproductive organ-expressed (TNFRSF1A modulator) | 0.80 | 4.7 × 10−2 |
212864_at | NM_003818 | CDS2 | CDP-diacylglycerol synthase (phosphatidate cytidyltransferase) 2 | 0.80 | 4.9 × 10−2 |
Hyperoxia/normoxia ratio of the median.
Welch t test performed to determine significant genes on the filtered set of 9,787 genes.
TABLE 3.
Affymetrix ID | Accession No. | Symbol | Gene | Ratio* | P Value† |
---|---|---|---|---|---|
219933_at | NM_016066 | GLRX2 | Glutaredoxin 2 | 1.57 | 1.8 × 10−3 |
201177_s_at | NM_005499 | UBA2 | SUMO-1 activating enzyme subunit 2 | 1.34 | 5.8 × 10−3 |
206020_at | NM_004232 | SOCS6 | Suppressor of cytokine signaling 6 | 1.36 | 6.1 × 10−3 |
219767_s_at | NM_005111 | CRYZL1 | Crystalline, zeta (quinone reductase)-like 1 | 1.26 | 8.0 × 10−3 |
213000_at | NM_015358 | ZCWCC3 | Zinc finger, CW-type with coiled-coil domain 3 | 1.53 | 8.1 × 10−3 |
205288_at | NM_003672 | CDC14A | CDC14 cell division cycle 14 homolog A (S. cerevisiae) | 1.78 | 8.6 × 10−3 |
201801_s_at | NM_004955 | SLC29A1 | Solute carrier family 29 (nucleoside transporters), member 1 | 1.31 | 8.9 × 10−3 |
200608_s_at | NM_006265 | RAD21 | RAD21 homolog (S. pombe) | 1.29 | 9.3 × 10−3 |
209146_at | NM_006745 | SC4MOL | Sterol-C4-methyl oxidase-like | 1.22 | 9.9 × 10−3 |
211746_x_at | NM_148976 | PSMA1 | Proteasome (prosome, macropain) subunit, alpha type, 1 | 1.41 | 1.0 × 10−2 |
213375_s_at | NM_052818 | CG018 | Hypothetical gene CG018 | 1.46 | 1.1 × 10−2 |
204449_at | NM_005388 | PDCL | Phosducin-like | 1.59 | 1.1 × 10−2 |
203827_at | NM_017983 | FLJ10055 | Hypothetical protein FLJ10055 | 1.37 | 1.1 × 10−2 |
212388_at | XM_371254 | USP24 | Ubiquitin specific protease 24 | 1.41 | 1.1 × 10−2 |
212510_at | NM_015141 | KIAA0089 | KIAA0089 protein | 1.36 | 1.3 × 10−2 |
203855_at | NM_014969 | KIAA0893 | KIAA0893 protein | 1.21 | 1.4 × 10−2 |
201816_s_at | NM_001483 | GBAS | Glioblastoma amplified sequence | 1.29 | 1.5 × 10−2 |
221182_at | NM_025063 | FLJ23550 | Hypothetical protein FLJ23550 | 1.29 | 1.5 × 10−2 |
212929_s_at | NM_001005751 | LOC387680, FLJ10824 | Similar to KIAA0592 protein hypothetical protein FLJ10824 | 1.30 | 1.6 × 10−2 |
201803_at | NM_000938 | POLR2B | Polymerase (28) II (DNA directed) polypeptide B, 140 kD | 1.16 | 1.7 × 10−2 |
209448_at | NM_006410 | HTATIP2 | HIV-1 Tat interactive protein 2, 30 kD | 1.17 | 1.8 × 10−2 |
211953_s_at | NM_002271 | KPNB3 | Karyopherin (importin) β 3 | 1.49 | 1.9 × 10−2 |
208678_at | NM_001696 | ATP6V1E1 | ATPase, H+ transporting, lysosomal 31 kD, V1 subunit E isoform 1 | 1.32 | 2.0 × 10−2 |
217851_s_at | NM_016045 | C20orf45 | Chromosome 20 open reading frame 45 | 1.46 | 2.1 × 10−2 |
208788_at | NM_021814 | ELOVL5 | ELOVL family member 5, elongation of long chain fatty acids (FEN1/Elo2, SUR4/Elo3-like, yeast) | 1.25 | 2.1 × 10−2 |
201784_s_at | NM_014267 | SMAP | Small acidic protein | 1.49 | 2.2 × 10−2 |
65493_at | NM_022070 | ABC1 | Amplified in breast cancer 1 | 1.44 | 2.2 × 10−2 |
200775_s_at | NM_002140 | HNRPK | Heterogeneous nuclear ribonucleoprotein K | 1.56 | 2.3 × 10−2 |
213530_at | BC022977 | RAB3GAP | RAB3 GTPase-activating protein | 1.16 | 2.4 × 10−2 |
213246_at | XM_058628 | C14orf109 | Chromosome 14 open reading frame 109 | 1.36 | 2.4 × 10−2 |
217853_at | NM_022748 | TENS1 | Tensin-like SH2 domain containing 1 | 1.44 | 2.4 × 10−2 |
208848_at | NM_000671 | ADH5 | Alcohol dehydrogenase 5 (class III), chi polypeptide | 1.69 | 2.4 × 10−2 |
208638_at | NM_005742 | TXNDC7 | Thioredoxin domain containing 7 (protein disulfide isomerase) | 1.31 | 2.4 × 10−2 |
212819_at | NM_016114 | ASB1 | Ankyrin repeat and SOCS box-containing 1 | 1.62 | 2.4 × 10−2 |
215884_s_at | NM_013444 | UBQLN2 | Ubiquilin 2 | 1.43 | 2.5 × 10−2 |
212543_at | XM_166300 | AIM1 | Absent in melanoma 1 | 1.14 | 2.5 × 10−2 |
208736_at | NM_005719 | ARPC3 | Actin related protein 2/3 complex, subunit 3, 21kDa | 1.18 | 2.7 × 10−2 |
204201_s_at | NM_006264 | PTPN13 | Protein tyrosine phosphatase, non-receptor type 13 (APO-1/CD95 (Fas)-associated phosphatase) | 1.26 | 2.7 × 10−2 |
207483_s_at | NM_018448 | TIP120A | TBP-interacting protein | 1.25 | 2.7 × 10−2 |
208857_s_at | NM_005389 | PCMT1 | Protein-L-isoaspartate (D-aspartate) O-methyltransferase | 1.32 | 2.7 × 10−2 |
219800_s_at | NM_024838 | THNSL1 | Threonine synthase-like 1 (bacterial) | 1.78 | 2.8 × 10−2 |
212519_at | NM_003341 | UBE2E1 | Ubiquitin-conjugating enzyme E2E 1 (UBC4/5 homolog, yeast) | 1.29 | 2.8 × 10−2 |
220495_s_at | NM_024715 | C5orf14 | Chromosome 5 open reading frame 14 | 1.36 | 2.8 × 10−2 |
209043_at | NM_005443 | PAPSS1 | 3′-phosphoadenosine 5′-phosphosulfate synthase 1 | 1.22 | 2.9 × 10−2 |
211936_at | NM_005347 | HSPA5 | Heat shock 70-kD protein 5 (glucose-regulated protein, 78 kD) | 1.44 | 2.9 × 10−2 |
218333_at | NM_016041 | F-LANa | Carcinoma-related gene | 1.50 | 2.9 × 10−2 |
217737_x_at | NM_016407 | C20orf43 | Chromosome 20 open reading frame 43 | 1.16 | 2.9 × 10−2 |
202872_at | NM_001695 | ATP6V1C1 | ATPase, H+ transporting, lysosomal 42kDa, V1 subunit C, isoform 1 | 1.48 | 3.0 × 10−2 |
213848_at | NM_001947 | DUSP7 | Dual specificity phosphatase 7 | 1.30 | 3.0 × 10−2 |
202271_at | NM_015176 | KIAA0483 | KIAA0483 protein | 1.35 | 3.0 × 10−2 |
212698_s_at | NM_144710 | SEPT10 | Septin 10 | 1.25 | 3.1 × 10−2 |
201676_x_at | NM_148976 | PSMA1 | Proteasome (prosome, macropain) subunit, alpha type, 1 | 1.17 | 3.1 × 10−2 |
206262_at | NM_000669 | ADH1C | Alcohol dehydrogenase 1C (class I), gamma polypeptide | 1.74 | 3.1 × 10−2 |
203181_x_at | NM_182691 | SRPK2 | SFRS protein kinase 2 | 1.60 | 3.1 × 10−2 |
211760_s_at | NM_003762 | VAMP4 | Vesicle-associated membrane protein 4 | 1.21 | 3.2 × 10−2 |
200979_at | NM_000284 | PDHA1 | Pyruvate dehydrogenase (lipoamide) alpha 1 | 1.26 | 3.2 × 10−2 |
201443_s_at | NM_005765 | ATP6AP2 | ATPase, H+ transporting, lysosomal accessory protein 2 | 1.30 | 3.2 × 10−2 |
209273_s_at | NM_030940 | HBLD2 | HESB like domain containing 2 | 1.33 | 3.3 × 10−2 |
212936_at | NM_032042 | DKFZP564D172 | Hypothetical protein DKFZp564D172 | 1.41 | 3.3 × 10−2 |
212841_s_at | BC021714 | PPFIBP2 | PTPRF interacting protein, binding protein 2 (liprin beta 2) | 1.39 | 3.5 × 10−2 |
222016_s_at | NM_145909 | ZNF323 | Zinc finger protein 323 | 1.82 | 3.5 × 10−2 |
211744_s_at | NM_001779 | CD58 | CD58 antigen, (lymphocyte function-associated antigen 3) | 1.46 | 3.6 × 10−2 |
201021_s_at | NM_006870 | DSTN | Destrin (actin depolymerizing factor) | 1.54 | 3.6 × 10−2 |
210968_s_at | NM_020532 | RTN4 | Reticulon 4 | 1.19 | 3.7 × 10−2 |
209174_s_at | NM_017730 | FLJ20259 | FLJ20259 protein | 1.35 | 3.7 × 10−2 |
202868_s_at | NM_006627 | POP4 | Processing of precursor 4, RNase P/MRP subunit (S. cerevisiae) | 1.21 | 3.7 × 10−2 |
201592_at | NM_003756 | EIF3S3 | Eukaryotic translation initiation factor 3, subunit 3 gamma, 40kDa | 1.24 | 3.7 × 10−2 |
211971_s_at | NM_133259 | LRPPRC | Leucine-rich PPR-motif containing | 1.24 | 3.8 × 10−2 |
203773_x_at | NM_000712 | BLVRA | Biliverdin reductase A | 1.49 | 3.8 × 10−2 |
203218_at | NM_002752 | MAPK9 | Mitogen-activated protein kinase 9 | 1.47 | 3.8 × 10−2 |
209004_s_at | NM_012161 | FBXL5 | F-box and leucine-rich repeat protein 5 | 1.18 | 3.8 × 10−2 |
202049_s_at | NM_005095 | ZNF262 | Zinc finger protein 262 | 1.29 | 3.8 × 10−2 |
213940_s_at | NM_015033 | FNBP1 | Formin binding protein 1 | 1.47 | 3.9 × 10−2 |
200992_at | NM_006391 | IPO7 | Importin 7 | 1.28 | 3.9 × 10−2 |
215440_s_at | XM_043653 | BEXL1 | Brain expressed X-linked-like 1 | 1.41 | 3.9 × 10−2 |
202474_s_at | NM_005334 | HCFC1 | Host cell factor C1 (VP16-accessory protein) | 1.27 | 4.0 × 10−2 |
221637_s_at | NM_024099 | MGC2477 | Hypothetical protein MGC2477 | 1.34 | 4.0 × 10−2 |
200684_s_at | NM_003347 | UBE2L3 | Ubiquitin-conjugating enzyme E2L 3 | 1.38 | 4.1 × 10−2 |
219751_at | NM_024860 | FLJ21148 | Hypothetical protein FLJ21148 | 1.39 | 4.1 × 10−2 |
202854_at | NM_000194 | HPRT1 | Hypoxanthine phosphoribosyltransferase 1 (Lesch-Nyhan syndrome) | 1.30 | 4.1 × 10−2 |
209340_at | NM_003115 | UAP1 | UDP-N-acteylglucosamine pyrophosphorylase 1 | 1.26 | 4.2 × 10−2 |
209034_at | NM_006813 | PNRC1 | Proline-rich nuclear receptor coactivator 1 | 1.94 | 4.2 × 10−2 |
200780_x_at | NM_000516 | GNAS | GNAS complex locus | 1.31 | 4.3 × 10−2 |
200941_at | NM_001537 | HSBP1 | Heat shock factor binding protein 1 | 1.09 | 4.3 × 10−2 |
212956_at | XM_093895 | KIAA0882 | KIAA0882 protein | 1.27 | 4.3 × 10−2 |
201200_at | NM_003851 | CREG | Cellular repressor of E1A-stimulated genes | 1.44 | 4.4 × 10−2 |
218065_s_at | NM_020644 | C11orf15 | Chromosome 11 open reading frame 15 | 1.19 | 4.6 × 10−2 |
202865_at | NM_001002762 | DNAJB12 | DnaJ (HSP40) homolog, subfamily B, member 12 | 1.27 | 4.6 × 10−2 |
202193_at | NM_005569 | LIMK2 | LIM domain kinase 2 | 1.24 | 4.6 × 10−2 |
217731_s_at | NM_021999 | ITM2B | Integral membrane protein 2B | 1.74 | 4.6 × 10−2 |
206158_s_at | NM_003418 | ZNF9 | Zinc finger protein 9 | 1.27 | 4.7 × 10−2 |
209005_at | NM_012161 | FBXL5 | F-box and leucine-rich repeat protein 5 | 1.36 | 4.7 × 10−2 |
209063_x_at | NM_006451 | PAIP1 | Poly(A) binding protein interacting protein 1 | 1.17 | 4.8 × 10−2 |
212017_at | AL137406 | LOC130074 | Hypothetical protein LOC130074 | 1.20 | 5.0 × 10−2 |
201202_at | NM_002592 | PCNA | Proliferating cell nuclear antigen | 1.33 | 5.0 × 10−2 |
Hyperoxia/normoxia ratio of the median.
Welch t test performed to determine significant genes on the filtered set of 9,787 genes.
TABLE 4.
Total* | Under* | Over* | P Value | |
---|---|---|---|---|
Molecular Function | ||||
Catalytic activity | ||||
Nucleotidyl transferase activity | 63 | 1 | 4 | 4 × 10−3 |
Protein tyrosine phosphatase activity | 39 | 0 | 4 | 4 × 10−3 |
Protein tyrosine/serine/threonine phosphatase activity | 20 | 0 | 2 | 4.2 × 10−2 |
Ubiquitin conjugating enzyme activity | 18 | 0 | 2 | 3.5 × 10−2 |
Oxidoreductase activity | ||||
Acting on aldehyde oroxo group of donors | 19 | 1 | 1 | 4 × 10−2 |
Formaldehyde dehydrogenase (glutathione) activity | 1 | 0 | 1 | 1.6 × 10−2 |
Alcohol dehydrogenase activity | 6 | 0 | 2 | 4 × 10−3 |
Transcription cofactor activity | 134 | 2 | 4 | 2.3 × 10−2 |
Corepressor activity | 46 | 1 | 2 | 4 × 10−2 |
Small GTPase binding | 18 | 0 | 2 | 3.5 × 10−2 |
Ran GTPase binding | 4 | 0 | 2 | 2 × 10−3 |
Unknown | 235 | 2 | 7 | 1.5 × 10−2 |
Biological Process | ||||
Regulation of DNA replication | 8 | 1 | 1 | 7 × 10−3 |
Proteolysis during cellular protein catabolism | 93 | 1 | 4 | 1.8 × 10−2 |
Ubiquitin-dependent protein catabolism | 81 | 1 | 4 | 1 × 10−2 |
Protein import into nucleus, docking | 13 | 0 | 2 | 1.9 × 10−2 |
Protein modification | 679 | 5 | 13 | 2.6 × 10−2 |
Phosphorus metabolism | 370 | 3 | 8 | 3.9 × 10−2 |
Protein amino acid dephosphorylation | 67 | 0 | 4 | 2.4 × 10−2 |
Number of genes modulated by hyperoxia and number of genes in each category on U133 array. Over- or under-representation of functional categories according to the GO classification are determined by using Fisher's exact test. Categories containing more than two genes and a P value < 0.05 are represented.
Selected Pathways and Categories of Interest from the Functional Analysis
Antioxidants, redox-related genes, and glutathione metabolism.
Antioxidant enzymes including the superoxide dismutases (SOD), catalase, glutamylcysteine ligase (GCL), or glutathione peroxidases (GPx) were not significantly modulated by hyperoxia (Table 5). The functional analysis identified genes with oxidoreductase activity instead (Table 4). This group includes alcohol dehydrogenases especially involved in the metabolism of lipid peroxidation products, suggesting a pivotal role of redox homeostasis in hyperoxia response. The glutathione metabolism category was not identified by functional analyses. However, genes related to glutathione/thiol metabolism were significantly modulated in the gene expression analysis, such as glutaredoxin 2 (GLRX2) and alcohol dehydrogenase 5 (ADH5). GLRX2 catalyzes the glutathione-dependent reduction of disulfides and glutathione-mixed disulfides in the mitochondrion (18, 28), whereas ADH5, a ubiquitous protein widely distributed in mammals, acts as a glutathione-dependent formaldehyde dehydrogenase, controlling intracellular levels of S-nitrosoglutathione, S-nitrosylated proteins, and the metabolism of lipid peroxidation products (29, 30). Together these enzymes contribute to cellular redox homeostasis.
TABLE 5.
Category | Description | Hyp/Nor ratio | P Value |
---|---|---|---|
Catalase and superoxide dismutase | Catalase | 1.27 | 0.084 |
Superoxide dismutase 1 | 1.05 | 0.683 | |
Superoxide dismutase 2 | 1.38 | 0.687 | |
Glutathione metabolism | Glutathione peroxidase 1 | 1.51 | 0.35 |
Glutathione peroxidase 4 | 1.12 | 0.613 | |
Glutathione peroxidase 2 | 0.92 | 0.798 | |
Glutathione peroxidase 3 | 1.03 | 0.74 | |
Glutathione-S-transferase A1 | 1.05 | 0.614 | |
Glutathione-S-transferase A2 | 1.30 | 0.298 | |
Glutathione-S-transferase A3 | 0.94 | 0.865 | |
Glutathione-S-transferase A4 | 1.17 | 0.502 | |
Glutathione-S-transferase M1 | 0.84 | 0.481 | |
Glutathione-S-transferase M2 | 0.94 | 0.808 | |
Glutathione-S-transferase M3 | 0.80 | 0.564 | |
Glutathione-S-transferase M4 | 0.73 | 0.122 | |
Glutathione-S-transferase M5 | 0.75 | 0.125 | |
Glutathione-S-transferase pi | 0.98 | 0.963 | |
Glutathione-S-transferase subunit 13 | 1.09 | 0.636 | |
Glutathione-S-transferase theta 1 | 0.98 | 0.952 | |
Microsomal glutathione S-transferase 2 | 0.97 | 0.923 | |
Glutathione-S-transferase omega 1 | 1.38 | 0.389 | |
Glutathione synthetase | 1 | 0.99 | |
Glutamate cysteine ligase (catalytic subunit) | 1.11 | 0.328 | |
Glutamate cysteine ligase (modifier subunit) | 1.17 | 0.217 | |
Glutaredoxin 2 | 1.57 | 0.002 | |
Glutaredoxin (thioltransferase) | 1.38 | 0.118 | |
Redox balance | Ferredoxin 1 | 1.28 | 0.252 |
Ferredoxin reductase | 1.11 | 0.656 | |
Peroxiredoxin 1 | 1.05 | 0.587 | |
Peroxiredoxin 2 | 1.00 | 1 | |
Peroxiredoxin 3 | 1.18 | 0.079 | |
Peroxiredoxin 4 | 1.34 | 0.396 | |
Peroxiredoxin 6 | 1.18 | 0.181 | |
Thioredoxin | 1.24 | 0.387 | |
Thioredoxin 2 | 1.11 | 0.697 | |
Thioredoxin interacting protein | 1.11 | 0.366 | |
Thioredoxin reductase 1 | 1.06 | 0.691 | |
Thioredoxin reductase 3 | 0.87 | 0.361 | |
Thioredoxin like, 32kDa | 1.15 | 0.274 | |
Thioredoxin-like 2 | 0.98 | 0.839 | |
Thioredoxin domain containing | 1.16 | 0.478 | |
Thioredoxin domain containing 4 | 1.04 | 0.681 | |
Thioredoxin domain containing 5 | 1.04 | 0.864 | |
Thioredoxin domain containing 7 | 1.31 | 0.024 | |
Thioredoxin-related transmembrane protein 2 | 1.19 | 0.522 | |
Alcohol dehydrogenase 1C | 1.74 | 0.03 | |
Alcohol dehydrogenase 5 | 1.33 | 0.02 | |
Alcohol dehydrogenase 1A | 0.96 | 0.792 | |
Alcohol dehydrogenase 6 | 0.90 | 0.505 | |
Alcohol dehydrogenase 7 | 1.22 | 0.442 |
Ubiquitination and protein catabolism pathway.
The ubiquitin-dependent protein catabolism and protein modification categories were the foremost biological process identified by the functional analysis using the GOMINER approach (Table 4, Figure 3). Among the genes identified in this category were proteasome subunit α1 (PSMA1), ubiquitin-conjugating enzyme E2E1 (UBE2E1), ubiquitin-conjugating enzyme E2L3 (UBE2L3), ubiquitin-specific protease 24 (USP24), and PSMD9 (Table 3).
Genes involved in the response to stress and inflammation.
Chaperones from the heat shock 70-kD (HSP70) and 40-kD (HSP40) family were induced by hyperoxia; that is, heat shock 70-kD protein 5-glucose-regulated protein (HSPA5), which is the only heat shock from the endoplasmic reticulum in the set of 9,784 genes, and DnaJ (HSP40) homolog subfamily B member 12 (DNAJB12). This confirms previous reports of increase of HSP70 at the mRNA level in airway epithelial cells exposed to acute hyperoxia (6). There was no evidence of an increase in genes involved in the immune response or the acute-phase inflammatory response within 12 h of exposure to hyperoxia.
Cell cycle–related genes.
The GOMINER functional analysis suggested a state of cell cycle arrest. The main alterations of molecular function identified were the protein phosphatases, especially with tyrosine phosphatase activity—for example, dual specificity phosphatase 7 (DUSP7), protein tyrosine phosphatase, nonreceptor type 13 (PTPN13), cell division cycle 14 homolog A (CDC14A), and tensin-like SH2 domain-containing 1 (TENS1) (Table 4, Figure 3). This was reinforced by the identification of genes involved in phosphorus metabolism, especially protein dephosphorylation and the regulation of DNA replication, that is, the significant decrease in cyclin-dependent kinase 2 (CDK2), which is involved in the late phase of G1-S transition. These findings suggest that cell cycle arrest may be an adaptive early response to cellular stress.
In Vitro Hyperoxia
Increased ubiquitination of proteins in BET-1A cells.
To confirm the involvement of ubiquitin-dependent protein catabolism induced by hyperoxia at the RNA level, transformed airway epithelial BET-1A cells were exposed to hyperoxia in vitro. We used proteasome inhibitor ALLN at 50 μM to quantitate the total level of ubiquitination occurring over time. At this concentration there is no evidence of cell toxicity, as reported by other studies using ALLN (31, 32). Here, cells displayed a low level of ubiquitinated proteins at baseline, which increased rapidly in a time-dependent manner in response to hyperoxia exposure compared with room air exposure (Figure 4).
Increased expression of HSP 70 mRNA in BET-1A cells and HAEC.
Previous study showed that upregulation of HSP70 specifically protected a lung epithelial cell line against hyperoxia by attenuating hyperoxia-mediated lipid peroxidation and ATP depletion (33). Here, primary and transformed airway epithelial cells exposed to hyperoxia in vitro confirmed upregulation of HSP70 mRNA by Northern analysis by 24 h of exposure (Figure 5).
Adverse effects of proteasome inhibition on ATP levels and activation/cleavage of caspase 8.
To investigate the role of increased protein catabolism in cells acutely exposed to hyperoxia, airway epithelial cells were exposed to hyperoxia in the presence or absence of ALLN. No evidence of cell toxicity was observed with ALLN, which is consistent with previous studies using human airway epithelial cells (data not shown) (31, 32, 34). Total protein concentrations of cell lysates were similar in cells without ALLN and exposed to ALLN in the presence or absence of hyperoxia (all P > 0.7). To determine the functional consequence of blocking the proteasome pathway in terms of cell metabolism and cell death pathways, intracellular free ATP level was measured (35). Under hyperoxia, BET-1A cells increased intracellular ATP, which was consistent with the findings from the transcriptome analyses of human airway epithelium exposed to hyperoxia in vivo that identified upregulation of ATP synthesis as a significant biological pathway. However, the ALLN-pretreated cells exposed to hyperoxia were unable to increase the intracellular ATP level (Figure 6A). Since increased ATP is likely necessary to adjust cellular metabolism and homeostasis in stressed cells, the consequence in terms of cell death was evaluated by using caspase 8 cleavage as a marker of activation of cell death. Cleavage of caspase 8 was increased at 24 h and 48 h in hyperoxia-exposed BET-1A cells pretreated with ALLN, but not cells undergoing hyperoxia exposure only (Figure 6B). These results indicate that proteasome clearance of oxidant-damaged proteins is required for induction of energy production by the cell.
DISCUSSION
Using gene expression profiling, we identified the early integrated response of the human bronchial epithelium after hyperoxia exposure in vivo. This situation frequently occurs during the treatment of acute respiratory distress syndrome in the adult and the newborn, and represents an example of oxidative stress, which is a common final pathway involved in the pathogenesis of many airway diseases such as asthma, chronic obstructive pulmonary disease, and cystic fibrosis (4). Although the source of the oxidative stress differs among environmental exposure in which the oxidants are present in the inhaled air (e.g., hyperoxia, air pollution, cigarette smoke) and inflammatory airway diseases in which the inflammatory cells recruited to the airways produce ROS, the airway response to oxidants appears generally similar (1). Consistent with two genomic studies of human airway cells after oxidant stress induced by cigarette smoke in vivo, hyperoxia leads to a greater number of genes up-regulated than down-regulated (36, 37). This is in contrast to results from genomic analyses of whole lungs of mice exposed to hyperoxia using a similar approach to this study (38). This may be related to differences between human and murine gene responses, the use of whole murine lung tissue as opposed to our relatively pure bronchial epithelial cells obtained by brushing, or the use of different manufacturers' microarrays (36–38). Nevertheless, the fold change of responses in this study, that is, hyperoxia to normoxia ratio, for modulated genes was relatively low. One explanation may be the abundant protective levels of antioxidant scavenging molecules, including glutathione, in the extracellular epithelial lining fluid in vivo. This first barrier may attenuate the cellular epithelial oxidant stress in the first 12 h of hyperoxia exposure (1, 39).
Traditionally, complementary approaches were used to confirm individual genes identified in the gene expression analysis. Since the development of this powerful technology, the procedures for DNA microarrays have been carefully standardized from the design of the study to the extraction and treatment of the data to guarantee optimal confidence in the results (www.mged.org/Workgroups/MIAME/miame.html) (21, 22, 40). Recent studies validated changes in modulated genes similar in direction and magnitude when compared with semiquantitative RT-PCR (38, 41, 42). The new strategies developed to improve the validity of the analysis focus on the identification of sets of genes instead of individual genes by themselves (43, 44). In this study, we used the same approach, assuming that a set of genes displaying coordinated expression level is involved in a functional pathway. This approach is particularly well suited toward understanding the inherent complexity of biological systems; that is, the concept of systems biology is founded on models translating the results of global functional genomics into a comprehensive understanding of how organisms are organized and operate (45).
Here, the inability of the bronchial epithelium to upregulate antioxidant enzymes including SOD1, SOD2, and catalase, is in accordance with previous studies showing a relatively low level of antioxidant mRNAs at baseline without any increase after 24–48 h of hyperoxia exposure in humans (7, 12, 15). The antioxidant enzyme response is similar to that of humans in murine lungs but different than in the rat (38, 46, 47). Interestingly, transgenic models with overexpression or mice deficient in these enzymes do not show evidence of an essential role of SOD and catalase in preventing hyperoxia injury in murine lungs (46). One of the protective antioxidant systems in the airway is glutathione, which neutralizes oxidants and inhibits oxidant-induced intracellular signal transduction, thus attenuating proinflammatory cellular responses (4). Human airway epithelial cell lines, including 16-HBE, BEAS-2B, NCI-H292, and A549, increase intracellular glutathione within hours of hyperoxia exposure in vitro (15, 48, 49). The mechanism for the glutathione increase may be related in part to a rapid, but transient, increase of glutamylcysteine ligase, the rate-limiting enzyme in de novo synthesis of GSH; intracellular levels increase 4 h after hyperoxia in vitro and return to basal levels by 12 h (50). In this study, changes in glutamylcysteine ligase mRNA were not found, but the airways were sampled after 12 h of hyperoxia, and earlier time of induction would not have been detected. However, other interacting components of the glutathione-antioxidant system, including γ-glutamyltransferase, glutathione peroxidases, and glutathione reductase, were not induced in this study, or in previous in vitro studies of primary human bronchial epithelial cells and bronchial epithelial cell lines exposed to hyperoxia (15, 24, 49–51). Other data support that upregulation of glutathione antioxidant systems are not requisite for defense against hyperoxia (25, 38, 52, 53). For example, glutathione peroxidase 1–deficient mice do not have increased sensitivity to hyperoxia (52, 53). Moreover, depletion of glutathione does not increase the sensitivity of BEAS-2B cells to hyperoxia (15). Taken together, enzymes of the glutathione antioxidant system do not appear to be one of the essential early adaptive responses to in vivo hyperoxia at the transcriptional level.
Functional analyses suggest an early effect of hyperoxia is the inhibition of DNA replication and transcription together with increased phosphatases, which would lead to a decrease in the phosphorylation status of the cell, and a possible resultant protective growth arrest. This is consistent with previous studies in mammalian and human cells exposed to hyperoxia that show a block of the G1 to S phase progression in the cell cycle mediated by an increase in CDK inhibitor p21WAF1/CIP1 within the first 12 h (8, 32, 54–57). Cell cycle arrest may provide time for repair of damage sustained under hyperoxia stress, and thus avoid the replication and propagation of potentially hazardous mutations (8, 32, 56, 57). This conjecture may be supported by the decrease in CdK2 and the increase expression of genes from the protein dephosphorylation category in our study (8, 57).
The induction of genes related to the proteasome, ubiquitin-conjugation pathways, protein folding, and chaperone functions in this study suggests a carefully integrated and coordinated response to identify hyperoxia-related damaged proteins and perhaps direct them toward the protein catabolism pathway (5, 27, 58, 59). Early induction of heat shock proteins in response to hyperoxia is a well-known adaptive mechanism in the prevention of aggregation and repair of damaged cellular macromolecules, including oxidized proteins and lipids (58). Hyperoxia increases expression of HSP70 mRNA in primary bronchial epithelial cells in vitro (6), and HSP70 attenuates lipid peroxidation in the human airway epithelial cell line A549 exposed to hyperoxia (33). Here, upregulation of HSP70 was detected in response to hyperoxia in vivo and also confirmed in BET-1A and primary human airway epithelial cells exposed in vitro. Another important role of this molecular chaperone is to interact with the ubiquitin system (58). Ubiquitination is the process by which a polyubiquitin chain is added onto altered proteins, which allows the proteasome to recognize, bind, and unfold the ubiquitinated proteins, and subsequently digest them into small peptides (5, 26, 58, 60). Chaperones act as protein stabilizers, preventing aggregation of misfolded proteins before the ubiquitin-proteasome–dependent degradation pathway (58). Greater ubiquitination of proteins in cells exposed to hyperoxia was confirmed in vitro. Disturbance in the processing and degradation of proteins are implicated in the physiopathology of many diseases, such as cystic fibrosis, which was recently confirmed using the same approach (32, 43, 61); hence the ability to upregulate ubiquitin-proteasome pathway is likely an essential defense to prevent tissue injury as a result of accumulation of damaged and misfolded proteins. In fact, the critical function of increasing protein clearance in hyperoxia was confirmed through measures of cellular ATP and activation of cell death pathways under conditions of inhibition of proteasomal degradation of proteins.
The ability of the cell to produce ATP in response to hyperoxia is a pivotal event in prevention of injury. An increase in glucose consumption and ATP production has previously been reported in the A549 lung cancer cell line exposed to hyperoxia (33, 62). In this study, genes involved in glycolysis were not induced in vivo, consistent with studies in mice exposed to hyperoxia and studies of human airway epithelial cells from individuals who smoke cigarettes (36, 38). However, hyperoxia and resultant oxidant stress may mediate effects on protein function through both transcriptional events and post-translational protein modifications. Protein tyrosine nitration, a selective and reversible process, occurs during oxidative stress, and leads to inactivation of proteins including enzymes in glycolysis and in the TCA cycle, resulting in inhibition of energy production (63). Functional genomic analysis in this study indicates that hyperoxia upregulates proteins involved in ATP production. This was confirmed by the marked and rapid induction of ATP levels in cells exposed to hyperoxia in vitro. The lack of increase of ATP, and the activation of caspase 8, with proteasome blockade suggests that degradation and clearance of proteins, is critical for the increase of ATP production and avoidance of cell death. Notably, the absence of apoptosis in cells exposed to hyperoxia in vitro was shown in previous studies of human airway epithelial cells, in which the occurrence of cell death occurs after days of exposure but appears more suggestive of necrosis (64, 65). This transcriptional signature of genes involved in ATP production (especially mitochondrial oxidoreductase activity genes) and genes involved in protein degradation (including ubiquitins) is shared among other diseases including cystic fibrosis (43) and muscular atrophy (66). These reports highlight the importance of the interaction between these pathways as a common cellular response to stress. In an in vitro model of human fibroblast exposure to oxidative stress, the accumulation of oxidatively modified proteins correlates with the inability of the cell to maintain intracellular ATP, with subsequent occurrence of necrosis, rather than apoptosis (67). The cell death, whether by necrosis or apoptosis, of human bronchial epithelium in vivo requires further studies.
In summary, human bronchial epithelial cells display small variations in gene expression after exposure to in vivo hyperoxia. The functional categories involved are suggestive of cell cycle arrest and induction of cytoprotective chaperones and the ubiquitin-proteasome–dependent protein degradation system. Involvement of genes with oxidoreductase activity likely contribute to maintenance of reduced glutathione and thiols that are critical for oxidant-scavenging capacity and energy production. These responses, which occur within 12 h of hyperoxia exposure in vivo, may be effective in preserving homeostatic integrity of the airway in the short term; however, under conditions of sustained oxygen exposure and/or chronic oxidative stress, they may not be sufficient to safeguard against injury of the airway.
Acknowledgments
The authors thank the Gene Expression and Genotyping Facility of the Comprehensive Cancer Center at Case (CA43703).
This study was supported by AI70649, HL60917, and M01 RR018390 from the National Center for Research Resources. A.C. was supported by grants from the Collège des Professeurs de Pneumologie.
Originally Published in Press as DOI: 10.1165/rcmb.2005-0251OC on May 11, 2006
Conflict of Interest Statement: None of the authors has a financial relationship with a commercial entity that has an interest in the subject of this manuscript.
References
- 1.Comhair SA, Erzurum SC. Antioxidant responses to oxidant-mediated lung diseases. Am J Physiol Lung Cell Mol Physiol 2002;283:L246–L255. [DOI] [PubMed] [Google Scholar]
- 2.Heffner JE, Repine JE. Pulmonary strategies of antioxidant defense. Am Rev Respir Dis 1989;140:531–554. [DOI] [PubMed] [Google Scholar]
- 3.van der Vliet A, Cross CE. Oxidants, nitrosants, and the lung. Am J Med 2000;109:398–421. [DOI] [PubMed] [Google Scholar]
- 4.Rahman I, MacNee W. Oxidative stress and regulation of glutathione in lung inflammation. Eur Respir J 2000;16:534–554. [DOI] [PubMed] [Google Scholar]
- 5.Grune T, Reinheckel T, Davies KJ. Degradation of oxidized proteins in mammalian cells. FASEB J 1997;11:526–534. [PubMed] [Google Scholar]
- 6.Yoo JH, Erzurum SC, Hay JG, Lemarchand P, Crystal RG. Vulnerability of the human airway epithelium to hyperoxia: constitutive expression of the catalase gene in human bronchial epithelial cells despite oxidant stress. J Clin Invest 1994;93:297–302. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Comhair SA, Thomassen MJ, Erzurum SC. Differential induction of extracellular glutathione peroxidase and nitric oxide synthase 2 in airways of healthy individuals exposed to 100% O2 or cigarette smoke. Am J Respir Cell Mol Biol 2000;23:350–354. [DOI] [PubMed] [Google Scholar]
- 8.Barazzone C, Horowitz S, Donati YR, Rodriguez I, Piguet PF. Oxygen toxicity in mouse lung: pathways to cell death. Am J Respir Cell Mol Biol 1998;19:573–581. [DOI] [PubMed] [Google Scholar]
- 9.Carvalho CR, de Paula Pinto Schettino G, Maranhao B, Bethlem EP. Hyperoxia and lung disease. Curr Opin Pulm Med 1998;4:300–304. [DOI] [PubMed] [Google Scholar]
- 10.Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001;163:1723–1729. [DOI] [PubMed] [Google Scholar]
- 11.Comroe J. Oxygen toxicity: the effect of inhalation of high concentration of oxygen for 24 hours on normal men at sea level and at a simulated altitude of 18,000 feet. JAMA 1945;128:710–717. [Google Scholar]
- 12.Erzurum SC, Danel C, Gillissen A, Chu CS, Trapnell BC, Crystal RG. In vivo antioxidant gene expression in human airway epithelium of normal individuals exposed to 100% O2. J Appl Physiol 1993;75:1256–1262. [DOI] [PubMed] [Google Scholar]
- 13.Sackner MA, Landa J, Hirsch J, Zapata A. Pulmonary effects of oxygen breathing: a 6-hour study in normal men. Ann Intern Med 1975;82: 40–43. [DOI] [PubMed] [Google Scholar]
- 14.Danel C, Erzurum SC, Prayssac P, Eissa NT, Crystal RG, Herve P, Baudet B, Mazmanian M, Lemarchand P. Gene therapy for oxidant injury-related diseases: adenovirus-mediated transfer of superoxide dismutase and catalase cDNAs protects against hyperoxia but not against ischemia-reperfusion lung injury. Hum Gene Ther 1998;9:1487–1496. [DOI] [PubMed] [Google Scholar]
- 15.Pietarinen-Runtti P, Raivio KO, Saksela M, Asikainen TM, Kinnula VL. Antioxidant enzyme regulation and resistance to oxidants of human bronchial epithelial cells cultured under hyperoxic conditions. Am J Respir Cell Mol Biol 1998;19:286–292. [DOI] [PubMed] [Google Scholar]
- 16.Grune T, Merker K, Sandig G, Davies KJ. Selective degradation of oxidatively modified protein substrates by the proteasome. Biochem Biophys Res Commun 2003;305:709–718. [DOI] [PubMed] [Google Scholar]
- 17.Erzurum SC, Lemarchand P, Rosenfeld MA, Yoo JH, Crystal RG. Protection of human endothelial cells from oxidant injury by adenovirus-mediated transfer of the human catalase cDNA. Nucleic Acids Res 1993;21:1607–1612. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Lillig CH, Berndt C, Vergnolle O, Lonn ME, Hudemann C, Bill E, Holmgren A. Characterization of human glutaredoxin 2 as iron-sulfur protein: a possible role as redox sensor. Proc Natl Acad Sci USA 2005; 102:8168–8173. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Liu G, Loraine AE, Shigeta R, Cline M, Cheng J, Valmeekam V, Sun S, Kulp D, Siani-Rose MA. NetAffx: Affymetrix probesets and annotations. Nucleic Acids Res 2003;31:82–86. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998;95:14863–14868. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000;25:25–29. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Zeeberg BR, Feng W, Wang G, Wang MD, Fojo AT, Sunshine M, Narasimhan S, Kane DW, Reinhold WC, Lababidi S, et al. GoMiner: a resource for biological interpretation of genomic and proteomic data. Genome Biol 2003;4:R28. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Reddel RR, Ke Y, Gerwin BI, McMenamin MG, Lechner JF, Su RT, Brash DE, Park JB, Rhim JS, Harris CC. Transformation of human bronchial epithelial cells by infection with SV40 or adenovirus-12 SV40 hybrid virus, or transfection via strontium phosphate coprecipitation with a plasmid containing SV40 early region genes. Cancer Res 1988; 48:1904–1909. [PubMed] [Google Scholar]
- 24.Comhair SA, Bhathena PR, Farver C, Thunnissen FB, Erzurum SC. Extracellular glutathione peroxidase induction in asthmatic lungs: evidence for redox regulation of expression in human airway epithelial cells. FASEB J 2001;15:70–78. [DOI] [PubMed] [Google Scholar]
- 25.Wu BJ, Morimoto RI. Transcription of the human hsp70 gene is induced by serum stimulation. Proc Natl Acad Sci USA 1985;82:6070–6074. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Donati YR, Slosman DO, Polla BS. Oxidative injury and the heat shock response. Biochem Pharmacol 1990;40:2571–2577. [DOI] [PubMed] [Google Scholar]
- 27.Kolodziejski PJ, Musial A, Koo JS, Eissa NT. Ubiquitination of inducible nitric oxide synthase is required for its degradation. Proc Natl Acad Sci USA 2002;99:12315–12320. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Enoksson M, Fernandes AP, Prast S, Lillig CH, Holmgren A, Orrenius S. Overexpression of glutaredoxin 2 attenuates apoptosis by preventing cytochrome c release. Biochem Biophys Res Commun 2005;327:774–779. [DOI] [PubMed] [Google Scholar]
- 29.Liu L, Hausladen A, Zeng M, Que L, Heitman J, Stamler JS. A metabolic enzyme for S-nitrosothiol conserved from bacteria to humans. Nature 2001;410:490–494. [DOI] [PubMed] [Google Scholar]
- 30.Gaston B, Reilly J, Drazen JM, Fackler J, Ramdev P, Arnelle D, Mullins ME, Sugarbaker DJ, Chee C, Singel DJ, et al. Endogenous nitrogen oxides and bronchodilator S-nitrosothiols in human airways. Proc Natl Acad Sci USA 1993;90:10957–10961. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Gerber A, Heimburg A, Reisenauer A, Wille A, Welte T, Buhling F. Proteasome inhibitors modulate chemokine production in lung epithelial and monocytic cells. Eur Respir J 2004;24:40–48. [DOI] [PubMed] [Google Scholar]
- 32.Boncoeur E, Tabary O, Bonvin E, Muselet C, Fritah A, Lefait E, Redeuilh G, Clement A, Jacquot J, Henrion-Caude A. Oxidative stress response results in increased p21(WAF1/CIP1) degradation in cystic fibrosis lung epithelial cells. Free Radic Biol Med 2006;40:75–86. [DOI] [PubMed] [Google Scholar]
- 33.Wong HR, Menendez IY, Ryan MA, Denenberg AG, Wispe JR. Increased expression of heat shock protein-70 protects A549 cells against hyperoxia. Am J Physiol 1998;275:L836–L841. [DOI] [PubMed] [Google Scholar]
- 34.Wu HM, Wen HC, Lin WW. Proteasome inhibitors stimulate interleukin-8 expression via Ras and apoptosis signal-regulating kinase-dependent extracellular signal-related kinase and c-Jun N-terminal kinase activation. Am J Respir Cell Mol Biol 2002;27:234–243. [DOI] [PubMed] [Google Scholar]
- 35.Eguchi Y, Shimizu S, Tsujimoto Y. Intracellular ATP levels determine cell death fate by apoptosis or necrosis. Cancer Res 1997;57:1835–1840. [PubMed] [Google Scholar]
- 36.Hackett NR, Heguy A, Harvey BG, O'Connor TP, Luettich K, Flieder DB, Kaplan R, Crystal RG. Variability of antioxidant-related gene expression in the airway epithelium of cigarette smokers. Am J Respir Cell Mol Biol 2003;29:331–343. [DOI] [PubMed] [Google Scholar]
- 37.Spira A, Beane J, Shah V, Liu G, Schembri F, Yang X, Palma J, Brody JS. Effects of cigarette smoke on the human airway epithelial cell transcriptome. Proc Natl Acad Sci USA 2004;101:10143–10148. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Perkowski S, Sun J, Singhal S, Santiago J, Leikauf GD, Albelda SM. Gene expression profiling of the early pulmonary response to hyperoxia in mice. Am J Respir Cell Mol Biol 2003;28:682–696. [DOI] [PubMed] [Google Scholar]
- 39.Comhair SA, Lewis MJ, Bhathena PR, Hammel JP, Erzurum SC. Increased glutathione and glutathione peroxidase in lungs of individuals with chronic beryllium disease. Am J Respir Crit Care Med 1999;159: 1824–1829. [DOI] [PubMed] [Google Scholar]
- 40.Kaminski N, Friedman N. Practical approaches to analyzing results of microarray experiments. Am J Respir Cell Mol Biol 2002;27:125–132. [DOI] [PubMed] [Google Scholar]
- 41.Spira A, Beane J, Pinto-Plata V, Kadar A, Liu G, Shah V, Celli B, Brody JS. Gene expression profiling of human lung tissue from smokers with severe emphysema. Am J Respir Cell Mol Biol 2004;31:601–610. [DOI] [PubMed] [Google Scholar]
- 42.Irizarry RA, Warren D, Spencer F, Kim IF, Biswal S, Frank BC, Gabrielson E, Garcia JG, Geoghegan J, Germino G, et al. Multiple-laboratory comparison of microarray platforms. Nat Methods 2005;2: 345–350. [DOI] [PubMed] [Google Scholar]
- 43.Wright JM, Merlo CA, Reynolds JB, Zeitlin PL, Garcia JGN, Guggino WB, Boyle MP. Respiratory epithelial gene expression in patients with mild and severe cystic fibrosis lung disease. Am J Respir Cell Mol Biol 2006;35:327–336. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Gruber MP, Coldren CD, Woolum MD, Cosgrove GP, Zeng C, Baron AE, Moore MD, Cool CD, Worthen GS, Brown KK, et al. Human lung project: evaluating variance of gene expression in the human lung. Am J Respir Cell Mol Biol 2006;35:65–71. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Strange K. The end of “naive reductionism”: rise of systems biology or renaissance of physiology? Am J Physiol Cell Physiol 2005;288:C968–C974. [DOI] [PubMed] [Google Scholar]
- 46.Waxman AB, Einarsson O, Seres T, Knickelbein RG, Warshaw JB, Johnston R, Homer RJ, Elias JA. Targeted lung expression of interleukin-11 enhances murine tolerance of 100% oxygen and diminishes hyperoxia-induced DNA fragmentation. J Clin Invest 1998;101:1970–1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Ho YS, Dey MS, Crapo JD. Antioxidant enzyme expression in rat lungs during hyperoxia. Am J Physiol 1996;270:L810–L818. [DOI] [PubMed] [Google Scholar]
- 48.Rahman I, Mulier B, Gilmour PS, Watchorn T, Donaldson K, Jeffery PK, MacNee W. Oxidant-mediated lung epithelial cell tolerance: the role of intracellular glutathione and nuclear factor-kappaB. Biochem Pharmacol 2001;62:787–794. [DOI] [PubMed] [Google Scholar]
- 49.Ray S, Watkins DN, Misso NL, Thompson PJ. Oxidant stress induces gamma-glutamylcysteine synthetase and glutathione synthesis in human bronchial epithelial NCI-H292 cells. Clin Exp Allergy 2002;32: 571–577. [DOI] [PubMed] [Google Scholar]
- 50.Rahman I, Bel A, Mulier B, Donaldson K, MacNee W. Differential regulation of glutathione by oxidants and dexamethasone in alveolar epithelial cells. Am J Physiol 1998;275:L80–L86. [DOI] [PubMed] [Google Scholar]
- 51.van Klaveren RJ, Demedts M, Nemery B. Cellular glutathione turnover in vitro, with emphasis on type II pneumocytes. Eur Respir J 1997;10: 1392–1400. [DOI] [PubMed] [Google Scholar]
- 52.Cho HY, Jedlicka AE, Reddy SP, Kensler TW, Yamamoto M, Zhang LY, Kleeberger SR. Role of NRF2 in protection against hyperoxic lung injury in mice. Am J Respir Cell Mol Biol 2002;26:175–182. [DOI] [PubMed] [Google Scholar]
- 53.Ho YS, Magnenat JL, Bronson RT, Cao J, Gargano M, Sugawara M, Funk CD. Mice deficient in cellular glutathione peroxidase develop normally and show no increased sensitivity to hyperoxia. J Biol Chem 1997;272:16644–16651. [DOI] [PubMed] [Google Scholar]
- 54.McGrath SA. Induction of p21WAF/CIP1 during hyperoxia. Am J Respir Cell Mol Biol 1998;18:179–187. [DOI] [PubMed] [Google Scholar]
- 55.Corroyer S, Maitre B, Cazals V, Clement A. Altered regulation of G1 cyclins in oxidant-induced growth arrest of lung alveolar epithelial cells: accumulation of inactive cyclin E-DCK2 complexes. J Biol Chem 1996;271:25117–25125. [DOI] [PubMed] [Google Scholar]
- 56.O'Reilly MA, Staversky RJ, Watkins RH, Reed CK, de Mesy Jensen KL, Finkelstein JN, Keng PC. The cyclin-dependent kinase inhibitor p21 protects the lung from oxidative stress. Am J Respir Cell Mol Biol 2001;24:703–710. [DOI] [PubMed] [Google Scholar]
- 57.Helt CE, Staversky RJ, Lee YJ, Bambara RA, Keng PC, O'Reilly MA. The Cdk and PCNA domains on p21Cip1 both function to inhibit G1/S progression during hyperoxia. Am J Physiol Lung Cell Mol Physiol 2004;286:L506–L513. [DOI] [PubMed] [Google Scholar]
- 58.Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. Nature 2003;426:895–899. [DOI] [PubMed] [Google Scholar]
- 59.Horibe T, Gomi M, Iguchi D, Ito H, Kitamura Y, Masuoka T, Tsujimoto I, Kimura T, Kikuchi M. Different contributions of the three CXXC motifs of human protein-disulfide isomerase-related protein to isomerase activity and oxidative refolding. J Biol Chem 2004;279:4604–4611. [DOI] [PubMed] [Google Scholar]
- 60.Ciechanover A. Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol 2005;6:79–87. [DOI] [PubMed] [Google Scholar]
- 61.Zeitlin PL, Gail DB, Banks-Schlegel S. Protein processing and degradation in pulmonary health and disease. Am J Respir Cell Mol Biol 2003; 29:642–645. [DOI] [PubMed] [Google Scholar]
- 62.Allen CB, White CW. Glucose modulates cell death due to normobaric hyperoxia by maintaining cellular ATP. Am J Physiol 1998;274:L159–L164. [DOI] [PubMed] [Google Scholar]
- 63.Aulak KS, Koeck T, Crabb JW, Stuehr DJ. Dynamics of protein nitration in cells and mitochondria. Am J Physiol Heart Circ Physiol 2004;286: H30–H38. [DOI] [PubMed] [Google Scholar]
- 64.Kazzaz JA, Xu J, Palaia TA, Mantell L, Fein AM, Horowitz S. Cellular oxygen toxicity. Oxidant injury without apoptosis. J Biol Chem 1996; 271:15182–15186. [DOI] [PubMed] [Google Scholar]
- 65.Mantell LL, Lee PJ. Signal transduction pathways in hyperoxia-induced lung cell death. Mol Genet Metab 2000;71:359–370. [DOI] [PubMed] [Google Scholar]
- 66.Lecker SH, Jagoe RT, Gilbert A, Gomes M, Baracos V, Bailey J, Price SR, Mitch WE, Goldberg AL. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J 2004;18:39–51. [DOI] [PubMed] [Google Scholar]
- 67.Miyoshi N, Oubrahim H, Chock PB, Stadtman ER. Age-dependent cell death and the role of ATP in hydrogen peroxide-induced apoptosis and necrosis. Proc Natl Acad Sci USA 2006;103:1727–1731. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Dudoit SD, Y. Y., Callow MJ, Speed TP. Statistical methods for identifying differently expressed genes in replicated cDNA microarray experiments. Technical Report #578. Stanford: Stanford University; 2000. p. 38.